Clinical traction HypnoVR has validated efficacy in pain and anxiety reduction through 15 clinical studies, including a 3.57x shorter postoperative stay and a 45% reduction in morphine use, signaling a strong value proposition for perioperative settings and potential hospital adoption.

Strategic partnerships Already integrated with major procurement networks and hospital groups (UniHA, UGAP, CAHPP, Helpevia, Vivalto Santé, Elsan) and available directly, presenting ready access to a wide network of anesthesia, surgery, and dental care buyers.

Acquisition momentum Recent acquisition of Oncomfort SA expands capability in digital sedation and positions HypnoVR to offer a broader, end-to-end VR-based therapeutic portfolio to hospitals seeking non-drug pain and anxiety management options.

Financing signals With total funding around $6.8M and revenue under $1M, there is likely appetite among investors and customers for scalable deployments, pilot programs, and expansion into additional hospital networks and international markets.

Tech and compliance fit Hardware-software medical device with fixed and mobile setups, compliant with healthcare hygiene standards, and supported by a broad tech stack; this suggests easy integration into existing hospital IT ecosystems and potential cross-sell with digital health and VR initiatives.